Dalan Animal Health

What Dalan Animal Health does

Dalan Animal Health is a privately held biotechnology company founded in 2018 and headquartered in Athens, Georgia, that develops vaccines for invertebrate species using its proprietary Innate Immunity Platform. Its lead product is the world's first USDA-conditionally licensed vaccine for honeybees, a killed Paenibacillus larvae bacterin that protects against American Foulbrood. The vaccine is administered orally to queen bees via queen candy, and immunity is transferred to offspring through Transgenerational Immune Priming (TGIP), a mechanism in which inactivated bacteria are transported via vitellogenin protein to the ovaries and deposited in eggs, priming larvae before they hatch. The company has also extended the platform to a first-in-class shrimp vaccine in development targeting White Spot Syndrome Virus and Early Mortality Syndrome for the $45 billion global shrimp aquaculture industry, with a strategic partnership with INVE (January 2026) supporting global aquaculture distribution.

The commercial model combines direct sales to large commercial beekeepers (quote-based for orders covering >50 hives) with a retail partner network across the USA and Canada including Mann Lake, Dadant, Honey Bee Genetics, Woodcamp Farm, and Dancing Bee Equipment. Partners sell both the vaccine and vaccinated queen bees and package bees, with vaccinated queens carrying approximately a $10 retail premium. Veterinary distribution serves as an additional channel, particularly in Canada where CFIA regulations require veterinary prescription. The company has demonstrated commercial traction with 20,000+ hives vaccinated and reports of 30–50% reduction in larval mortality, 83% effectiveness against Deformed Wing Virus-B, and 90% lower DWV-B viral loads in vaccinated colonies.

Across four disclosed funding rounds plus the December 2025 Yuyu Pharma strategic investment, Dalan has raised approximately $12.3M from Prime Movers Lab, At One Ventures, Good Growth Capital, Meach Cove Capital, and other backers. The company holds a USPTO Notice of Allowance on its foundational edible-vaccination patent, regulatory approvals in the US (conditional) and Canada (full market authorization), and European market entry underway via a subsidiary that secured a €250K pan-European surveillance grant. Recognition includes TIME Best Inventions 2023, Fast Company Next Big Thing in Tech 2023, the George Washington Carver Award (2024), and the TCRS Innovation Award (2025). Headcount sits in the 11–50 range, consistent with early commercial-stage operations.

Name

Dalan Animal Health

Legal name

Dalan Animal Health, Inc.

Website

https://dalan.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Dalan Animal Health is a biotechnology company that has developed the world's first USDA-approved vaccine for honeybees and is extending its Transgenerational Immune Priming platform to shrimp aquaculture, serving commercial and hobbyist beekeepers and the global $45B shrimp industry.

Ownership category

akta.pro rank

Product category

Veterinary Biologics and Animal Health Vaccines

NAICS

Veterinary Services (541940)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Wildlife & Zoo/Exotic Animal Vaccines (HLAMAKAG)

akta.pro secondary industries

Aquaculture/Fish & Shrimp Vaccines (HLAMAKAE), Veterinary Vaccines (HLAIAEAH)

Keywords

• Veterinary biologics
• Honeybee health
• Aquaculture vaccines
• Transgenerational immunity
• Insect vaccines

Headquarters

HQ city

Athens

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. Honeybee Vaccine Sales: Dalan sells its Paenibacillus larvae bacterin vaccine directly to beekeepers and through retail partners. The product is sold as 50-dose vials, with minimum orders of 50 doses. Commercial beekeepers with >50 hives can request quotes directly from the company. The vaccine provides a prophylactic, sustainable alternative to antibiotics for American Foulbrood prevention.
2. Vaccinated Queen and Package Sales: Dalan distributes vaccinated queen bees and package bees through certified partner retailers. Vaccinated queens command a premium price, typically $10 markup compared to non-vaccinated queens. Partners include Mann Lake, Honey Bee Genetics, Woodcamp Farm, Dancing Bee Equipment, Dadant, and others across the USA and Canada.
3. Shrimp Vaccine (Development Stage): The company is developing a first-in-class shrimp vaccine targeting White Spot Syndrome Virus (WSSV) and Early Mortality Syndrome (EMS) for the $45 billion global shrimp industry. The $3M SAFE funding round (November 2025) is specifically supporting commercialization efforts, regulatory approval, manufacturing scale-up, and market development for this product.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Dalan Animal Health develops and commercializes biological vaccines for invertebrate species that lack adaptive immune systems, using a proprietary Transgenerational Immune Priming (TGIP) platform. Its flagship commercial product is the world's first USDA-approved vaccine for honeybees, protecting against American Foulbrood disease, and it is extending the platform into aquaculture with a first-in-class shrimp vaccine targeting White Spot Syndrome Virus and Early Mortality Syndrome.

Product overview

Dalan Animal Health is a biotechnology company that has developed an Innate Immunity Platform technology enabling vaccine development for invertebrate species. The company's portfolio consists of two core products: the Honeybee Vaccine (Paenibacillus Larvae Bacterin), which is the world's first USDA-conditionally licensed vaccine for an insect species protecting against American Foulbrood disease, and the Shrimp Vaccine, a first-in-class vaccine in development targeting White Spot Syndrome Virus (WSSV) and Early Mortality Syndrome (EMS) for the $45 billion global shrimp industry. Both products utilize transgenerational immune priming (TGIP) technology, where vaccines are administered to maternal animals and immunity is passed to offspring before hatching. The platform has potential applications across other aquaculture species and poultry.

Differentiator

Problem solved

Functional benefit

Products and services

• Honeybee Vaccine (Paenibacillus Larvae Bacterin) The world's first USDA-conditionally licensed vaccine for honeybees, protecting against American Foulbrood disease caused by Paenibacillus larvae. Administered orally to queen bees via queen candy (one 3ml 50-dose vial mixed with 300g candy; 6g administered per queen cage), with immunity passed to offspring through Transgenerational Immune Priming (TGIP). Non-GMO, contains no chemicals or harmful preservatives, and is suitable for organic agriculture. Sold to commercial beekeepers (>50 hives) via direct quote-based sales and to smaller beekeepers via pre-order of vaccinated queens and packages through retail partner network (Mann Lake, Dadant, Honey Bee Genetics, Dancing Bee Equipment, etc.) in the USA and Canada.
• Vaccinated Queen Bees and Package Bees Live queen bees and package bees that have been vaccinated using Dalan's Paenibacillus larvae bacterin vaccine, distributed through certified partner retailers including Mann Lake (California and Kentucky), Honey Bee Genetics (California), Woodcamp Farm (Maryland), Dancing Bee Equipment (Canada), Dadant (USA), White Mountain Apiary (New Hampshire), Heitkams' Honey Bees (California), Can-Am Apiaries (California), Brawes Bee Farm (North Carolina), Meyer Bees (Illinois), Foley's Russian Bees (Iowa), and Buzz's Bees (California). Vaccinated queens command approximately a $10 premium per queen compared to non-vaccinated queens and offer built-in American Foulbrood resistance to downstream beekeeping customers.

Quantifiable outcome

• 30-50% reduction in larval mortality from American Foulbrood
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• INVE (part of the SHIC network)coreStrategic or Co-development Partner · 16 January 2026Strategic partnership to advance shrimp disease prevention through vaccination strategies and scalable solutions. Dalan and INVE are joining forces to strengthen shrimp health and sustainability worldwide, leveraging Dalan's vaccine technology with INVE's aquaculture expertise and distribution network.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Ceva Animal Health: Top-5 global animal health company and leading veterinary biologics manufacturer. Directly comparable because Dalan's CSO Erin Strait was previously Director of Innovation at Ceva, and Ceva operates in poultry, swine, and aquaculture vaccines — overlapping with Dalan's pipeline and current platform focus.
• Zoetis: Largest pure-play animal health company globally, with leading vaccine franchises across livestock and companion animals. Comparable as the dominant animal biologics incumbent; Dalan board member Linda Rhodes sits on Zoetis's board, underscoring how closely Dalan competes for the same biologics innovation space.
• Merck Animal Health: Division of Merck operating one of the world's broadest veterinary vaccine portfolios. Comparable as a major animal-vaccine incumbent; Dalan's CSO previously led U.S. Swine Biologics discovery at Merck Animal Health, evidencing direct technical overlap and competition for talent and customers.
• Boehringer Ingelheim Animal Health: Global top-3 animal health company with leading swine, poultry, and aquaculture vaccine franchises. Comparable because Dalan's Nigel Swift previously led global vaccine R&D at BI following its Merial acquisition, making BI a direct incumbent competing for similar species and aquaculture customers.
• Elanco Animal Health: Large-cap pure-play animal health company with vaccine and therapeutic portfolios across species. Comparable as a broad incumbent in animal biologics competing for the same disease-prevention budgets across livestock, aquaculture, and companion animals.
• Vetoquinol: Mid-to-large animal health company with biologics and pharmaceutical portfolios across livestock and companion animals. Comparable as another broad incumbent developing vaccines for production animals, directly overlapping with Dalan's pipeline ambition.
• Phibro Animal Health: Animal health company with vaccines, nutritional specialties, and aquaculture health products. Comparable as an incumbent with overlapping aquaculture health and livestock vaccine portfolios targeting many of the same species and disease problems as Dalan's platform.
• Virbac: Global animal health company with strong biologics and vaccine portfolio across species. Comparable as a broad incumbent in veterinary vaccines and aquaculture health, competing for the same innovation and customer relationships Dalan seeks to enter.

Direct peers

• HIPRA: Spanish veterinary biologics company specializing in vaccines for livestock and aquaculture. Most comparable as a similarly-sized specialist vaccine developer with strong R&D focus, competing for the same species-vaccine customers Dalan is targeting with its platform.
• INVE (Benchmark Holdings): Leading aquaculture health and nutrition company and Dalan's January 2026 strategic partner for the shrimp vaccine. Comparable as both a collaborator and adjacent aquaculture-health competitor with deep shrimp-farmer relationships that determine market access for Dalan's shrimp product.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@dalananimalhealth
• Facebookfacebook.com/Dalan-Animal-Health-105306081351119
• LinkedInlinkedin.com/company/dalan-animal-health-inc
• Instagraminstagram.com/dalananimalhealth
• Xx.com/dalanbeehealth

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dalan Animal Health